Drug Trial Radar · NCT05039099
A Study to Evaluate, Safety, Tolerability, and PK of AP-101 in Participants With ALS
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Sep 2, 2021
Primary completion
Aug 13, 2025
Study completion Aug 13, 2025
Sponsor
- Lead sponsor
- AL-S PharmaIndustry
- Sponsor type
- Industry
- First posted
- Sep 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
AP-101Drug
Participants receive AP-101 by intravenous infusion (IV).
PlaceboDrug
Participants receive placebo by intravenous infusion (IV).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Serious Adverse Events (TESAE) During the Double-Blind PeriodTime frame: From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
- Number of Participants With Abnormalities in Vital Signs, Clinical Laboratory Assessments, Physical and Neurological Examinations, and ElectrocardiogramsTime frame: From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
- Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs) During the Double-Blind PeriodTime frame: From baseline through the 21-day follow-up after Week 24, approximately 27 weeks
Locations
13 sites in 6 countries. Site status is shown where the registry gives one.
UC San Diego, ACTRI
La Jolla, California
Department of Neurology, University Hospitals
Leuven, Belgium
ALS clinic at the Kaye Edmonton Clinic, University of Alberta
Edmonton, Alberta, Canada
London Health Sciences Centre - Victoria Hospital
London, Ontario, Canada
ALS Research Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Montreal Neurological Institute and Hospital / Dr Genge
Montreal, Quebec, Canada
Charité
Berlin, Germany
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Bonn, Germany
Hannover Medical School
Hanover, Germany
Ulm University Hospital
Ulm, Germany
Hanyang University Medical Center
Seoul, South Korea
Studieenheten Akademiskt specialistcentrum, SLSO
Stockholm, Sweden
Norrlands universitetssjukhus/ University Hospital of Northern Sweden (NUS)
Umeå, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.